Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 51NIH 10INDUSTRY 8NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Specimen Handling 67Magnetic Resonance Spectroscopy 52Cyclophosphamide 44Vincristine 37Radiotherapy 30Radiation 30Cisplatin 30Carboplatin 29Dexamethasone 27Etoposide 26Doxorubicin 25Biopsy 25daratumumab 17Radiotherapy, Intensity-Modulated 17Prednisone 17Paclitaxel 16Irinotecan 16Cytarabine 16durvalumab 15Platinum 15Gemcitabine 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 141,2-diaminocyclohexaneplatinum II citrate 14Lenalidomide 13X-Rays 12Watchful Waiting 12Rituximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × blinatumomab × 1 year × Clear all
NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡